About Hulio®

Hulio® is an approved biosimilar of adalimumab. It is a recombinant human monoclonal antibody (mAB). Adalimumab is the third tumour necrosis factor alpha (TNFα)-blocking agent available in the form of a biosimilar, following infliximab (another monoclonal antibody, mAb) and etanercept (a fusion protein).1

Mechanism of Action

Hulio® has been developed as a biosimilar of adalimumab, which is approved by the European Medicines Agency (EMA)2 and has undergone a thorough regulatory review process. Hulio® has demonstrated biosimilarity to reference product in terms of pharmacokinetics, clinical efficacy, safety and immunogenicity.3,4

As an adalimumab biosimilar, Hulio® inhibits TNFα – a mediator of inflammation in immune-mediated diseases. By specifically binding to TNFα, adalimumab blocks its activity, thereby reducing inflammation and other disease symptoms.5

Hulio® for Chronic Inflammatory Diseases

Hulio® is indicated as second-line therapy for the treatment of chronic inflammatory conditions in children and adults, such as rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and IBD (Crohn’s disease and ulcerative colitis). It is indicated in cases of active or severe disease, or in instances where first-line therapy is not tolerated or denied.7 Hulio® aids in improving the current symptoms and also helps in preventing future complications.

Hulio® Biosimilar

In the last 2 decades, the treatment of immune-mediated diseases has been revolutionised. Initially, the treatment of immune-mediated diseases involved analgesics and non-steroidal anti-inflammatory drugs (NSAIDs), which have now advanced with the introduction of biologics. Biological therapies are targeted at the immune system, providing an alternative to the existing treatment methods. However, the high cost of these drugs has prevented their wider use.6

The availability of biosimilars has brought about a huge change in the treatment of chronic inflammatory diseases as these agents can improve affordability and promote wider and earlier access to often life-changing therapeutic interventions.7 Therefore, the role of Hulio® biosimilar is crucial here. The major distinguishing factor of Hulio® is its affordability compared with the reference product while still offering comparable safety, efficacy and tolerability.

Hulio® is available in 3 presentations: pre-filled syringe, pre-filled pen and vial (for paediatric use).2 The pre-filled pen is designed to be easy to use for patients.2

Restricted access

The website you are trying to access is designed for healthcare professionals only - the content is not designed for the general public.

Are you a healthcare professional based in UK or Ireland?

YES
NO

Report side effects

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare providers are asked to report any suspected adverse reactions. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. In order to support effective tracking and traceability of biologics including biosimilars, it is recommended that the brand name and batch number are recorded and used when reporting adverse events.

You are now leaving the Hulio® uk website